Plus Therapeutics Inc (PSTV) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.03 (-0.49%), Market cap $0.04B, 52-week low–high $0.16 ~ $7.62.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to
Financial statements, price targets, institutional (13F) holdings and related news for Plus Therapeutics Inc are updated in real time on BlackAll Trade.
Plus Therapeutics Inc trades at $2.03 (-0.49%). Real-time quotes and charts are available on BlackAll Trade.
Plus Therapeutics Inc has a market cap of about $0.04B.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherape